A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines

Autor: M C, Hancock, B C, Langton, T, Chan, P, Toy, J J, Monahan, R P, Mischak, L K, Shawver

Publikováno v: Cancer research. 51(17)

A monoclonal antibody (TAb 250) specific to an extracellular epitope of the c-erbB-2 protein (gp185) inhibited the in vitro proliferation of human breast tumor cell lines that overexpress c-erbB-2 in a dose-dependent manner. Treatment of cells with c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1b30094a967df0a3c89eb477ff6e7b4e
https://pubmed.ncbi.nlm.nih.gov/1678683

Monoclonal antibodies and immobilized antibodies

Autor: Robert J. Linhardt, C. W. Abell, R. M. Denney, B. W. Altrock, R. Auerbach, S. D. Bernal, R. E. Canfield, P. H. Ehrlich, W. R. Moyle, T. S. Chan, T. W. Chang, N. T. Chang, J. A. Cidlowski, M. D. Viceps, R. J. Cote, D. M. Morrissey, A. N. Houghton, E. J. Beattie, H. F. Oettgen, L. J. Old, C. M. Croce, R. S. Cubicciotti, A. E. Karu, R. M. Krauss, J. S. Cullor, A. Deutsch, H. Brandwein, H. Platt, D. M. Hunter, A. Dubitsky, S. M. Durham, F. A. Dolbeare, J. W. Gray, G. R. Dreesman, C. E. Kendall, J. C. Egrie, A. R. Frackelton, H. N. Eisen, A. H. Ross, S. Gay, G. Geirnaert, J. E. Geltosky, E. H. Goldberg, E. Goldwasser, C. Kavinsky, T. L. Weiss, H. G. Gratzner, B. Hampar, M. Zweig, S. D. Showalter, H. H. Handley, M. C. Glassy, Y. Hagiwara, H. Hagiwara, C. M. Huang, S. N. Cohen, J. V. Hughes, E. M. Scolnick, J. E. Tomassini, R. Jefferis, J. Steensgaard, H. S. Kaplan, N. N. H. Teng, K. S. Earn, R. F. Calvo, L. Kass, J. R. Kettman, M. V. Norgard, M. B. Khazaeli, W. H. Beierwaltes, B. G. England, P. C. Kung, G. Goldstein, L. Lanier, J. Phillips, N. L. Warner, J. W. Larrick, A. R. Raubitschek, K. E. Truitt, H. Lazarus, J. F. Schwaber, J. Lewicki, C. Lewis, J. V. Olander, W. R. Tolbert, E. L. Milford, C. B. Carpenter, J. M. Paradysz, D. F. Mosher, J. L. Mulshine, J. D. Minna, K. A. Murray, D. M. Neville, R. J. Youle, M. Nicolson, I. Pastan, M. C. Willingham, D. J. Fitzgerald, A. Pucci, A. M. Smithyman, M. B. Slade, P. W. French, G. Wijffels, C. S. Pukel, K. O. Lloyd, L. R. Travassos, W. G. Dippold, R. P. Reckel, J. L. Harris, R. Wellerson, S. M. Shaw, P. M. Kaplan, E. L. Reinherz, S. F. Schlossman, S. C. Mener, J. Sakamoto, C. C. Cordon, E. Friedman, C. L. Finstad, W. E. Enker, M. R. Melamed, J. F. Oettgen, P. J. Scannon, L. E. Spitler, H. M. Lee, R. T. Kawahata, R. P. Mischak, J. Schlom, D. Colcher, M. Nuti, P. H. Hand, F. Austin, G. D. Shockman, D. E. Jackson, W. Wong, Z. Steplewski, H. Koprowski, M. Herlyn, M. Strand, I. S. Trowbridge, D. L. Urdal, C. J. March, S. K. Dower, J. R. Wands, V. R. Zurawski, C. A. White, R. Dulbecco, W. R. Allen, E. C. Arnold, M. Flasher, H. H. Freedman, T. D. Heath, P. Shek, D. Papahadjopoulos, M. Ikeda, S. Sakamoto, K. Suzuki, M. Kuboyama, Y. Harada, A. Kawashiri, E. Takahashi, H. S. Lee, S. Margel, R. C. Nowinski, A. S. Hoffman, J. W. Peterson, K. B. Platt, D. E. Reed, F. X. Real, M. J. Mattes, P. O. Livingston, A. Rembaum, R. C. K. Yen, R. Rosenstein, B. Schneider

Publikováno v: Applied Biochemistry and Biotechnology. 15:53-80

Antibodies in both their free and immobilized state have been the object of considerable industrial and academic interest. A variety of methods are used for preparing and immobilizing antibodies. Applications for monoclonal antibodies include the pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::53b3e2a60fa089ffc4619eece666554b
https://doi.org/10.1007/bf02798506

Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin

Autor: L E, Spitler, M, del Rio, A, Khentigan, N I, Wedel, N A, Brophy, L L, Miller, W S, Harkonen, L L, Rosendorf, H M, Lee, R P, Mischak

Publikováno v: Cancer research. 47(6)

We conducted a trial of a murine monoclonal antimelanoma antibody-ricin A chain immunotoxin (XOMAZYME-MEL) in 22 patients with metastatic malignant melanoma. The dose of immunotoxin administered ranged from 0.01 mg/kg daily for 5 days to 1 mg/kg dail

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::197116ded51fcb34917fc2c4947db3cb
https://pubmed.ncbi.nlm.nih.gov/3493066